Clinical Trial Update: A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating the combination of rapamycin and trastuzumab in HER-2 receptor positive metastatic breast cancer; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Rapamycin (sirolimus)

Snippet

Sponsor: Yale University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-09-21